{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:00:41Z","timestamp":1794200441183,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1F1A1074102"],"award-info":[{"award-number":["2022R1F1A1074102"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aims to figure out the worldwide prevalence of anticancer therapy-associated acute kidney injury (AKI) and tubulointerstitial nephritis (TIN) and the relative risk of each cancer drug. We conducted an analysis of VigiBase, the World Health Organization pharmacovigilance database, 1967\u20132023 via disproportionate Bayesian reporting method. We further categorized the anticancer drugs into four groups: cytotoxic therapy, hormone therapy, immunotherapy, and targeted therapy. Reporting odds ratio (ROR) and information component (IC) compares observed and expected values to investigate the associations of each category of anticancer drugs with AKI and TIN. We identified 32,722 and 2056 reports (male, n\u2009=\u200917,829 and 1,293) of anticancer therapy-associated AKI and TIN, respectively, among 4,592,036 reports of all-drug caused AKI and TIN. There has been a significant increase in reports since 2010, primarily due to increased reports of targeted therapy and immunotherapy. Immunotherapy exhibited a significant association with both AKI (ROR: 8.92; IC<jats:sub>0.25<\/jats:sub>: 3.06) and TIN (21.74; 4.24), followed by cytotoxic therapy (7.14; 2.68), targeted therapy (5.83; 2.40), and hormone therapy (2.59; 1.24) for AKI, and by cytotoxic therapy (2.60; 1.21) and targeted therapy (1.54; 0.61) for TIN. AKI and TIN were more prevalent among individuals under 45\u00a0years of age, with a female preponderance for AKI and males for TIN. These events were reported in close temporal relationship after initiation of the respective drug (16.53\u00a0days for AKI and 27.97\u00a0days for TIN), and exhibited a high fatality rate, with 23.6% for AKI and 16.3% for TIN. These findings underscore that kidney-related adverse drug reactions are of prognostic significance and strategies to mitigate such side effects are required to optimize anticancer therapy.<\/jats:p>","DOI":"10.1038\/s41598-024-67020-x","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T12:01:55Z","timestamp":1720785715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023"],"prefix":"10.1038","volume":"14","author":[{"given":"Soo-Young","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sooji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeongmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sug","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Seok","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeri","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyunghwan","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"67020_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"KB Tran","year":"2022","unstructured":"Tran, K. B. et al. The global burden of cancer attributable to risk factors, 2010\u201319: A systematic analysis for the global burden of disease study 2019. Lancet 400, 563\u2013591. https:\/\/doi.org\/10.1016\/S0140-6736(22)01438-6 (2022).","journal-title":"Lancet"},{"key":"67020_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: From T cell basic science to clinical practice. Nat Rev Immunol 20, 651\u2013668. https:\/\/doi.org\/10.1038\/s41577-020-0306-5 (2020).","journal-title":"Nat Rev Immunol"},{"key":"67020_CR3","unstructured":"Organization, W. H. WHO methods and data sources for life tables 1990-2019, <https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-life-expectancy-and-healthy-life-expectancy> (Dec 2020)."},{"key":"67020_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/s1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian, M. J. et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21, 508\u2013518. https:\/\/doi.org\/10.1016\/s1470-2045(20)30074-7 (2020).","journal-title":"Lancet Oncol"},{"key":"67020_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djy167","volume":"111","author":"A Kitchlu","year":"2019","unstructured":"Kitchlu, A. et al. Acute kidney injury in patients receiving systemic treatment for cancer: A population-based cohort study. J Natl Cancer Inst 111, 727\u2013736. https:\/\/doi.org\/10.1093\/jnci\/djy167 (2019).","journal-title":"J Natl Cancer Inst"},{"key":"67020_CR6","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1038\/s41598-023-33122-1","volume":"13","author":"SY Yoon","year":"2023","unstructured":"Yoon, S. Y. et al. National trends in the prevalence of chronic kidney disease among Korean adults, 2007\u20132020. Sci Rep 13, 5831. https:\/\/doi.org\/10.1038\/s41598-023-33122-1 (2023).","journal-title":"Sci Rep"},{"key":"67020_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055870","volume":"8","author":"E Canet","year":"2013","unstructured":"Canet, E. et al. Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: Impact on remission and survival. PLoS One 8, e55870. https:\/\/doi.org\/10.1371\/journal.pone.0055870 (2013).","journal-title":"PLoS One"},{"key":"67020_CR8","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cam4.2140","volume":"8","author":"E Kang","year":"2019","unstructured":"Kang, E. et al. Acute kidney injury predicts all-cause mortality in patients with cancer. Cancer Med 8, 2740\u20132750. https:\/\/doi.org\/10.1002\/cam4.2140 (2019).","journal-title":"Cancer Med"},{"key":"67020_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/sj.ki.5002786","volume":"73","author":"N Pabla","year":"2008","unstructured":"Pabla, N. & Dong, Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int 73, 994\u20131007. https:\/\/doi.org\/10.1038\/sj.ki.5002786 (2008).","journal-title":"Kidney Int"},{"key":"67020_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00216-4","volume":"24","author":"EL Giraud","year":"2023","unstructured":"Giraud, E. L. et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: An update. Lancet Oncology 24, e229. https:\/\/doi.org\/10.1016\/S1470-2045(23)00216-4 (2023).","journal-title":"Lancet Oncology"},{"key":"67020_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29693","volume":"96","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database. J Med Virol 96, e29693. https:\/\/doi.org\/10.1002\/jmv.29693 (2024).","journal-title":"J Med Virol"},{"key":"67020_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29682","volume":"96","author":"YD Jeong","year":"2024","unstructured":"Jeong, Y. D. et al. Global and regional burden of vaccine-associated facial paralysis, 1967\u20132023: Findings from the WHO international pharmacovigilance database. J Med Virol 96, e29682. https:\/\/doi.org\/10.1002\/jmv.29682 (2024).","journal-title":"J Med Virol"},{"key":"67020_CR13","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","volume":"42","author":"J-E Salem","year":"2021","unstructured":"Salem, J.-E. et al. Anticancer drug-induced life-threatening ventricular arrhythmias: A World Health Organization pharmacovigilance study. Eur Heart J 42, 3915\u20133928. https:\/\/doi.org\/10.1093\/eurheartj\/ehab362 (2021).","journal-title":"Eur Heart J"},{"key":"67020_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","volume":"61","author":"M Haubitz","year":"2002","unstructured":"Haubitz, M. et al. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 61, 1495\u20131501. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00279.x (2002).","journal-title":"Kidney Int"},{"key":"67020_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1681\/ASN.2014010046","volume":"26","author":"D Geetha","year":"2015","unstructured":"Geetha, D. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Journal of the American Society of Nephrology 26, 976\u2013985 (2015).","journal-title":"Journal of the American Society of Nephrology"},{"key":"67020_CR16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","volume":"82","author":"NJ Ives","year":"2017","unstructured":"Ives, N. J. et al. Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer 82, 171\u2013183. https:\/\/doi.org\/10.1016\/j.ejca.2017.06.006 (2017).","journal-title":"Eur J Cancer"},{"key":"67020_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/acn3.84","volume":"1","author":"LH Kasper","year":"2014","unstructured":"Kasper, L. H. & Reder, A. T. Immunomodulatory activity of interferon-beta. Ann Clin Transl Neurol 1, 622\u2013631. https:\/\/doi.org\/10.1002\/acn3.84 (2014).","journal-title":"Ann Clin Transl Neurol"},{"key":"67020_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"67020_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n, G. N., Hopstadius, J. & Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res 22, 57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604 (2013).","journal-title":"Stat Methods Med Res"},{"key":"67020_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.54724\/lc.2022.e13","volume":"2","author":"C Min","year":"2022","unstructured":"Min, C. The importance of a world health organization international pharmacovigilance database (VigiBase): Novel methods for safety monitoring and surveillance of medical products. Life Cycle 2, 13. https:\/\/doi.org\/10.54724\/lc.2022.e13 (2022).","journal-title":"Life Cycle"},{"key":"67020_CR21","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1038\/s41467-024-48825-w","volume":"15","author":"Y Choi","year":"2024","unstructured":"Choi, Y. et al. Acute and post-acute respiratory complications of SARS-CoV-2 infection: Population-based cohort study in South Korea and Japan. Nat Commun 15, 4499. https:\/\/doi.org\/10.1038\/s41467-024-48825-w (2024).","journal-title":"Nat Commun"},{"key":"67020_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29591","volume":"96","author":"HG Woo","year":"2024","unstructured":"Woo, H. G. et al. Global burden of vaccine-associated multiple sclerosis, 1967\u20132022: A comprehensive analysis of the international pharmacovigilance database. J Med Virol 96, e29591. https:\/\/doi.org\/10.1002\/jmv.29591 (2024).","journal-title":"J Med Virol"},{"key":"67020_CR23","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.eururo.2014.01.026","volume":"66","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia, G. et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol 66, 1125\u20131132. https:\/\/doi.org\/10.1016\/j.eururo.2014.01.026 (2014).","journal-title":"Eur Urol"},{"key":"67020_CR24","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90, 638\u2013647. https:\/\/doi.org\/10.1016\/j.kint.2016.04.008 (2016).","journal-title":"Kidney Int"},{"key":"67020_CR25","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1200\/jco.1994.12.12.2714","volume":"12","author":"AS Guleria","year":"1994","unstructured":"Guleria, A. S. et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 12, 2714\u20132722. https:\/\/doi.org\/10.1200\/jco.1994.12.12.2714 (1994).","journal-title":"J Clin Oncol"},{"key":"67020_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw382","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine, H. et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transpl 32, 936\u2013942. https:\/\/doi.org\/10.1093\/ndt\/gfw382 (2017).","journal-title":"Nephrol Dial Transpl"},{"key":"67020_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali, A. C., Perazella, M. A. & Gettinger, S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68, 287\u2013291. https:\/\/doi.org\/10.1053\/j.ajkd.2016.02.057 (2016).","journal-title":"Am J Kidney Dis"},{"key":"67020_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2215\/cjn.06100616","volume":"12","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo, R. et al. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol 12, 176\u2013189. https:\/\/doi.org\/10.2215\/cjn.06100616 (2017).","journal-title":"Clin J Am Soc Nephrol"},{"key":"67020_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/ijms25010414","volume":"25","author":"K Moturi","year":"2023","unstructured":"Moturi, K., Sharma, H. & Hashemi-Sadraei, N. Nephrotoxicity in the age of immune checkpoint inhibitors: Mechanisms, diagnosis, and management. Int J Mol Sci 25, 414. https:\/\/doi.org\/10.3390\/ijms25010414 (2023).","journal-title":"Int J Mol Sci"},{"key":"67020_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","volume":"76","author":"S Gupta","year":"2020","unstructured":"Gupta, S. et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-Cell (CAR-T) therapy for diffuse large B-Cell lymphoma. Am J Kidney Dis 76, 63\u201371. https:\/\/doi.org\/10.1053\/j.ajkd.2019.10.011 (2020).","journal-title":"Am J Kidney Dis"},{"key":"67020_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.drup.2005.03.004","volume":"8","author":"R Board","year":"2005","unstructured":"Board, R. & Jayson, G. C. Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resist Updat 8, 75\u201383. https:\/\/doi.org\/10.1016\/j.drup.2005.03.004 (2005).","journal-title":"Drug Resist Updat"},{"key":"67020_CR32","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358, 1129\u20131136. https:\/\/doi.org\/10.1056\/NEJMoa0707330 (2008).","journal-title":"N Engl J Med"},{"key":"67020_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2023.115392","volume":"264","author":"J Kong","year":"2023","unstructured":"Kong, J. et al. Nephrotoxicity assessment of podophyllotoxin-induced rats by regulating PI3K\/Akt\/mTOR-Nrf2\/HO1 pathway in view of toxicological evidence chain (TEC) concept. Ecotoxicol Environ Saf 264, 115392. https:\/\/doi.org\/10.1016\/j.ecoenv.2023.115392 (2023).","journal-title":"Ecotoxicol Environ Saf"},{"key":"67020_CR34","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.34067\/kid.0003782020","volume":"1","author":"Y Gui","year":"2020","unstructured":"Gui, Y. & Dai, C. mTOR signaling in kidney diseases. Kidney 1, 1319\u20131327. https:\/\/doi.org\/10.34067\/kid.0003782020 (2020).","journal-title":"Kidney"},{"key":"67020_CR35","doi-asserted-by":"publisher","first-page":"114491","DOI":"10.1016\/j.biopha.2023.114491","volume":"161","author":"P Pandey","year":"2023","unstructured":"Pandey, P. et al. New insights about the PDGF\/PDGFR signaling pathway as a promising target to develop cancer therapeutic strategies. Biomed Pharm 161, 114491. https:\/\/doi.org\/10.1016\/j.biopha.2023.114491 (2023).","journal-title":"Biomed Pharm"},{"key":"67020_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/sj.ki.5002702","volume":"73","author":"H Kuwana","year":"2008","unstructured":"Kuwana, H. et al. The phosphoinositide-3 kinase \u03b3\u2013Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity. Kidney Int 73, 430\u2013445. https:\/\/doi.org\/10.1038\/sj.ki.5002702 (2008).","journal-title":"Kidney Int"},{"key":"67020_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1681\/asn.2015121308","volume":"28","author":"ED O'Sullivan","year":"2017","unstructured":"O\u2019Sullivan, E. D., Hughes, J. & Ferenbach, D. A. Renal aging: Causes and consequences. J Am Soc Nephrol 28, 407\u2013420. https:\/\/doi.org\/10.1681\/asn.2015121308 (2017).","journal-title":"J Am Soc Nephrol"},{"key":"67020_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1611391","volume":"376","author":"A Kaddourah","year":"2017","unstructured":"Kaddourah, A., Basu, R. K., Bagshaw, S. M. & Goldstein, S. L. Epidemiology of acute kidney injury in critically ill children and young adults. N Engl J Med 376, 11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611391 (2017).","journal-title":"N Engl J Med"},{"key":"67020_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41391-021-00415-3","volume":"26","author":"MV Sherer","year":"2023","unstructured":"Sherer, M. V. et al. Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy. Prostate Cancer Prostatic Dis 26, 276\u2013281. https:\/\/doi.org\/10.1038\/s41391-021-00415-3 (2023).","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"67020_CR40","doi-asserted-by":"publisher","first-page":"002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"JR Brahmer","year":"2021","unstructured":"Brahmer, J. R. et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9, 002435. https:\/\/doi.org\/10.1136\/jitc-2021-002435 (2021).","journal-title":"J Immunother Cancer"},{"key":"67020_CR41","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1681\/asn.2013080867","volume":"25","author":"ME Grams","year":"2014","unstructured":"Grams, M. E. et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol 25, 1834\u20131841. https:\/\/doi.org\/10.1681\/asn.2013080867 (2014).","journal-title":"J Am Soc Nephrol"},{"key":"67020_CR42","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2215\/CJN.04710420","volume":"15","author":"ED Poggio","year":"2020","unstructured":"Poggio, E. D. et al. Systematic review and meta-analysis of native kidney biopsy complications. Clin J Am Soc Nephrol 15, 1595\u20131602 (2020).","journal-title":"Clin J Am Soc Nephrol"},{"key":"67020_CR43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/ki.2010.89","volume":"77","author":"M Praga","year":"2010","unstructured":"Praga, M. & Gonz\u00e1lez, E. Acute interstitial nephritis. Kidney Int 77, 956\u2013961. https:\/\/doi.org\/10.1038\/ki.2010.89 (2010).","journal-title":"Kidney Int"},{"key":"67020_CR44","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/j.bja.2019.02.028","volume":"123","author":"DJ Magee","year":"2019","unstructured":"Magee, D. J., Jhanji, S., Poulogiannis, G., Farquhar-Smith, P. & Brown, M. R. D. Nonsteroidal anti-inflammatory drugs and pain in cancer patients: A systematic review and reappraisal of the evidence. Br J Anaesth 123, e412\u2013e423. https:\/\/doi.org\/10.1016\/j.bja.2019.02.028 (2019).","journal-title":"Br J Anaesth"},{"key":"67020_CR45","doi-asserted-by":"publisher","first-page":"cd03038","DOI":"10.1002\/14651858.CD003038.pub2","volume":"2013","author":"M Paul","year":"2013","unstructured":"Paul, M. et al. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane Database Syst Rev 2013, cd03038. https:\/\/doi.org\/10.1002\/14651858.CD003038.pub2 (2013).","journal-title":"Cochrane Database Syst Rev"},{"key":"67020_CR46","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2215\/cjn.00990119","volume":"14","author":"H Seethapathy","year":"2019","unstructured":"Seethapathy, H. et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14, 1692\u20131700. https:\/\/doi.org\/10.2215\/cjn.00990119 (2019).","journal-title":"Clin J Am Soc Nephrol"},{"key":"67020_CR47","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ekir.2017.02.008","volume":"2","author":"H Izzedine","year":"2017","unstructured":"Izzedine, H. & Perazella, M. A. Anticancer drug-induced acute kidney injury. Kidney Int Rep 2, 504\u2013514. https:\/\/doi.org\/10.1016\/j.ekir.2017.02.008 (2017).","journal-title":"Kidney Int Rep"},{"key":"67020_CR48","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.2215\/cjn.15681221","volume":"17","author":"S Gupta","year":"2022","unstructured":"Gupta, S., Gudsoorkar, P. & Jhaveri, K. D. Acute kidney injury in critically ill patients with cancer. Clin J Am Soc Nephrol 17, 1385\u20131398. https:\/\/doi.org\/10.2215\/cjn.15681221 (2022).","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67020-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67020-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67020-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T12:07:00Z","timestamp":1720786020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67020-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67020"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67020-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andreas Kronbichler received research grants from CSL Vifor and Otsuka, and fees for consultancy from CSL Vifor, Otsuka, Walden Biosciences, Catalyst Biosciences, AstraZeneca, Glaxo Smith Kline, Roche, and Delta4.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16124"}}